↓ Skip to main content
Embed badge What is this page?

Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil

Overview of attention for article published in BMC Infectious Diseases, August 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
56 Mendeley

What is this page?

Summary Twitter Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil
Published in
BMC Infectious Diseases, August 2017
DOI 10.1186/s12879-017-2669-1
Pubmed ID
28810911
Authors

D. M. P. Ramalho, P. F. C. Miranda, M. K. Andrade, T. Brígido, M. P. Dalcolmo, E. Mesquita, C. F. Dias, A. N. Gambirasio, J. Ueleres Braga, A. Detjen, P. P. J. Phillips, I. Langley, P. I. Fujiwara, S. B. Squire, M. M. Oliveira, A. L. Kritski

Abstract

The implementation of rapid drug susceptibility testing (DST) is a current global priority for TB control. However, data are scarce on patient-relevant outcomes for presumptive diagnosis of drug-resistant tuberculosis (pDR-TB) evaluated under field conditions in high burden countries. Observational study of pDR-TB patients referred by primary and secondary health units. TB reference centers addressing DR-TB in five cities in Brazil. Patients age 18 years and older were eligible if pDR-TB, culture positive results for Mycobacterium tuberculosis and, if no prior DST results from another laboratory were used by a physician to start anti-TB treatment. The outcome measures were median time from triage to initiating appropriate anti-TB treatment, empirical treatment and, the treatment outcomes. Between February,16th, 2011 and February, 15th, 2012, among 175 pDR TB cases, 110 (63.0%) confirmed TB cases with DST results were enrolled. Among study participants, 72 (65.5%) were male and 62 (56.4%) aged 26 to 45 years. At triage, empirical treatment was given to 106 (96.0%) subjects. Among those, 85 were treated with first line drugs and 21 with second line. Median time for DST results was 69.5 [interquartile - IQR: 35.7-111.0] days and, for initiating appropriate anti-TB treatment, the median time was 1.0 (IQR: 0-41.2) days. Among 95 patients that were followed-up during the first 6 month period, 24 (25.3%; IC: 17.5%-34.9%) changed or initiated the treatment after DST results: 16/29 MDRTB, 5/21 DR-TB and 3/45 DS-TB cases. Comparing the treatment outcome to DS-TB cases, MDRTB had higher proportions changing or initiating treatment after DST results (p = 0.01) and favorable outcomes (p = 0.07). This study shows a high rate of empirical treatment and long delay for DST results. Strategies to speed up the detection and early treatment of drug resistant TB should be prioritized.

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 56 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 14%
Researcher 8 14%
Student > Bachelor 6 11%
Student > Master 6 11%
Other 5 9%
Other 6 11%
Unknown 17 30%
Readers by discipline Count As %
Medicine and Dentistry 16 29%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Nursing and Health Professions 3 5%
Agricultural and Biological Sciences 3 5%
Immunology and Microbiology 3 5%
Other 5 9%
Unknown 22 39%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2017.
All research outputs
#15,475,586
of 22,997,544 outputs
Outputs from BMC Infectious Diseases
#4,526
of 7,718 outputs
Outputs of similar age
#198,790
of 316,580 outputs
Outputs of similar age from BMC Infectious Diseases
#100
of 167 outputs
Altmetric has tracked 22,997,544 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,718 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,580 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 167 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.